Status:
NOT_YET_RECRUITING
Multimodal Deep Learning for the Diagnosis and Assessment of Alzheimer's Disease
Lead Sponsor:
First Hospital of China Medical University
Conditions:
Alzheimer Disease
Mild Cognitive Impairment
Eligibility:
All Genders
50-85 years
Brief Summary
Alzheimer's disease (AD) is the most common dementia and has been one of the most expensive diseases with the highest lethality. With the rapid increase of the aging population, more and more burdens ...
Detailed Description
Our objective is to make the early diagnosis and assessment of AD and MCI based on multimodal deep learning. Initially, Gait disorder, facial expression identification dysfunction, and speech and lang...
Eligibility Criteria
Inclusion
- . Participants' age is between 50 and 85 years old, male or female;
- . Participants graduated from primary school or above, with normal hearing, vision, and pronunciation, using Chinese as their mother tongue and Mandarin as their daily language；
- . The diagnosis of AD and MCI participants conform to the corresponding diagnostic criteria mentioned above;
- . The scores of MMSE are between 10 and 28, and the scores of CDR are no more than 2.
- . Patients or family members agree to sign informed consent.
Exclusion
- . Participants suffer from neurological disorders that could cause dysfunction of the brain, such as depression, tumors, Parkinson's disease, metabolic encephalopathy, encephalitis, multiple sclerosis, epilepsy, brain trauma, normal cranial pressure hydrocephalus, and so forth;
- . Participants suffer from systematic diseases that could cause cognitive impairment, such as liver insufficiency, renal insufficiency, thyroid dysfunction, severe anemia, folic acid or vitamin B12 deficiency, syphilis, HIV infection, alcohol and drug abuse, and so forth;
- . Participants suffer from diseases that are unable to cooperate with the examinations;
- . Participants cannot take magnetic resonance imaging;
- . Participants suffer from mental and neurodevelopmental retardation;
- . Participants refuse to sign informed consent.
Key Trial Info
Start Date :
October 15 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
October 15 2026
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT06081569
Start Date
October 15 2023
End Date
October 15 2026
Last Update
October 13 2023
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.